Rigel Pharmaceuticals Set to Present R289 Data at ASH Annual Meeting 2025

Rigel Pharmaceuticals Prepares to Showcase Promising Data at ASH Annual Meeting

Rigel Pharmaceuticals, Inc. is gearing up for a significant presentation at the 67th American Society of Hematology (ASH) Annual Meeting, where it will unveil updated data from its ongoing Phase 1b study of R289, a dual IRAK1/4 inhibitor. This innovative therapy targets patients with relapsed or refractory lower-risk myelodysplastic syndrome (MDS), a hematologic disorder that presents a considerable unmet medical need. Despite the availability of current treatment options, the patient population continues to grapple with the effects of the disease, underscoring the importance of Rigel’s research in this area. The ASH meeting, scheduled for December 6-9, 2025, in Orlando and virtually, will provide Rigel with a platform to highlight advancements in its hematology and oncology portfolio.

Dr. Lisa Rojkjaer, Rigel's chief medical officer, expresses enthusiasm for the opportunity to discuss their latest findings, particularly the oral presentation that will detail the safety and efficacy results from the Phase 1b study of R289. As of the latest update on July 15, 2025, the study has enrolled 33 patients, primarily older adults with a median age of 75, many of whom have undergone multiple prior therapies and exhibit a high transfusion burden. The doses administered range from 250 mg once daily to 500 mg twice daily, with some participants still under evaluation. The forthcoming presentation, delivered by Dr. Guillermo Garcia-Manero, aims to provide insights into the potential of R289 as a new treatment option for patients suffering from this challenging condition.

In addition to the R289 study, Rigel will also present four poster sessions on REZLIDHIA® (olutasidenib), which targets mutated isocitrate dehydrogenase-1 (mIDH1) in relapsed or refractory acute myeloid leukemia (AML). These presentations aim to showcase the breadth of Rigel's commitment to addressing significant gaps in treatment options within hematologic malignancies. As the company continues to develop its pipeline, the upcoming ASH Annual Meeting stands as a critical moment to engage with the medical community, share its research advancements, and bolster its position within the biopharmaceutical landscape.

As Rigel Pharmaceuticals prepares for these presentations, it also approaches its quarterly earnings announcement on November 4, 2025. While the focus remains on advancing its clinical programs, investors are keenly anticipating updates on the company’s financial health and operational strategies. Analysts expect the earnings report to shed light on the company's revenue growth and ongoing collaborations that enhance its research and development capabilities. With a promising pipeline and strategic initiatives in place, Rigel’s upcoming disclosures could provide essential insights into the company’s trajectory in the biopharmaceutical industry.